chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pain in nasal area not navel; nauseas; feeling dizzy; it didn't feel right; ears still hurt; Felt fatigue, tired the whole day; Arm was sore; too sick to call; pain/pressure in her navel area; pain/pressure in ears; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (too sick to call), ABDOMINAL PAIN (pain/pressure in her navel area), EAR PAIN (pain/pressure in ears), DIZZINESS (feeling dizzy) and FEELING ABNORMAL (it didn't feel right) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included IRON for an unknown indication.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, the patient experienced ILLNESS (too sick to call), ABDOMINAL PAIN (pain/pressure in her navel area) and EAR PAIN (pain/pressure in ears). On 03-Apr-2021, the patient experienced FATIGUE (Felt fatigue, tired the whole day) and VACCINATION SITE PAIN (Arm was sore). On 04-Apr-2021, the patient experienced DIZZINESS (feeling dizzy), FEELING ABNORMAL (it didn't feel right), EAR DISCOMFORT (ears still hurt) and NAUSEA (nauseas). On an unknown date, the patient experienced RHINALGIA (pain in nasal area not navel). The patient was treated with ACETYLSALICYLIC ACID, CAFFEINE, PARACETAMOL (EXCEDRIN [ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL]) at an unspecified dose and frequency; CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency and IBUPROFEN (ADVIL [IBUPROFEN]) for Adverse event, at an unspecified dose and frequency. At the time of the report, ILLNESS (too sick to call), ABDOMINAL PAIN (pain/pressure in her navel area), DIZZINESS (feeling dizzy), FEELING ABNORMAL (it didn't feel right), EAR DISCOMFORT (ears still hurt), VACCINATION SITE PAIN (Arm was sore) and NAUSEA (nauseas) outcome was unknown and EAR PAIN (pain/pressure in ears), RHINALGIA (pain in nasal area not navel) and FATIGUE (Felt fatigue, tired the whole day) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medications were reported by the reporter.    Most recent FOLLOW-UP information incorporated above includes: On 24-Jul-2021: Event update/correction/event outcome : patient has clarified that she was suffering from Nasal Pain and not navel pain.
Trouble speaking; legs are swollen and numb; legs are swollen and numb; This is a spontaneous report from a contactable consumer. An 83-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) lot number: EN6202, via an unspecified route of administration, administered in left arm on 27Feb2021 18:00 as single dose for COVID-19 immunisation. Medical history included Parkinson's disease. Concomitant medications were not reported. The patient is not pregnant at the time of vaccination. The patient experienced trouble speaking, and legs are swollen and numb on 01Mar2021. The patient was hospitalized due to the events. No treatment was received. The outcome of the events was not recovered.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 35-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 08Sep2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 34 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Mar2023, outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Mar2023) Positive; (01Apr2023) Positive, notes: Previous positive test was on Saturday, 01Apr; (03Apr2023) Negative, notes: A negative test was performed on Monday, 03Apr and again on Wednesday 05Apr; (05Apr2023) Negative, notes: A negative test was performed on Monday, 03Apr and again on Wednesday 05Apr. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Injection site abscess. Small nodule under the skin lasting at least five days after injection. Abscess is still present.
Rash with tenderness, fever of 99.5F, chills, sweating, faintness and shortness of breath.
Right behind his teeth was swollen and inflamed; Behind his teeth was tender and sore; Swelling of the lymph nodes in his mouth; Soreness in the shoulder; This spontaneous case was reported by a consumer and describes the occurrence of PULPITIS DENTAL (Right behind his teeth was swollen and inflamed), TENDERNESS (Behind his teeth was tender and sore), LYMPHADENOPATHY (Swelling of the lymph nodes in his mouth) and ARTHRALGIA (Soreness in the shoulder) in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048B21A) for COVID-19 vaccination.     Concurrent medical conditions included Arthritis. Concomitant products included AMLODIPINE BESILATE, BENAZEPRIL HYDROCHLORIDE (AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE) for Blood pressure management, VITAMIN D [VITAMIN D NOS] for Supplementation therapy.    On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Apr-2021, the patient experienced PULPITIS DENTAL (Right behind his teeth was swollen and inflamed), LYMPHADENOPATHY (Swelling of the lymph nodes in his mouth) and ARTHRALGIA (Soreness in the shoulder). 30-Apr-2021, the patient experienced TENDERNESS (Behind his teeth was tender and sore). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency and NAPROXEN SODIUM (ALEVE) at an unspecified dose and frequency. At the time of the report, PULPITIS DENTAL (Right behind his teeth was swollen and inflamed) and LYMPHADENOPATHY (Swelling of the lymph nodes in his mouth) outcome was unknown and TENDERNESS (Behind his teeth was tender and sore) and ARTHRALGIA (Soreness in the shoulder) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information included steroid intravenously was noted.   This case was linked to MOD-2021-186979 (Patient Link).
Lump in right breast, was indicated by indentation. No other indications or possible side effects. Was removed surgically. 6 weeks from discovery to surgery.
Fever; loss of taste; This is a spontaneous report from a contactable consumer. A male patient of unknown age received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration on 24May2021 as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date and any other relevant medical history was reported as unknown. It was unknown if the patient had any known allergies. It was unknown if the patient had received any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25May2021 at 07:00, the patient experienced fever and loss of taste. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown if any therapeutic measures were taken for the events. The clinical outcome of the events fever and loss of taste were resolving at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
hearing loss; other zoster-related conditions; shingles; Information has been received from a lawyer and refers to a patient of unknown age and gender. The concurrent conditons, medical history and concomitant therapy were not reprted. On or about 03-DEC-2014, patient was inoculated with zoster vaccine live (ZOSTAVAX), as prescribed and/or administered by a pharmacist at a drug store for the long-term prevention of shingles and zoster-related conditions. Subsequent to patient's zoster vaccine live (ZOSTAVAX) inoculation, patient was treated by healthcare providers at a hospital located for shingles and other zoster-related conditions. Patient sought additional treatment by healthcare providers at primary care for hearing loss and other zoster-related conditions. As a direct and proximate result of patient's use of the zoster vaccine live (ZOSTAVAX) vaccine, patient has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The events were considered to be related to zoster vaccine live (ZOSTAVAX).  Upon internal review, the event of hearing loss was considered to be medically significant.
Within half hour of getting vaccine. I began to feel very tired. Went to sleep when I got home. The next day I had pain in right side of body, headache, dizziness, and weakness. Sensitivity to light. When I stood up I felt as if my bones were crumbling. I called my doctor, he gave me medication for dizziness. For the next month, I just didn't feel like myself. Headaches would come and go.
01/14/2021 102 fever, myalgias, exhaustion. Lasted about a day.  01/17/2021 hives on face, right ear, neck, chest, bilateral hands and bilateral feet for 5 days.  Washed gently with clear water, patted dry, used Benedryl, Benedryl cream and bag balm. None helped.  No new laundry soap, bath soaps, foods etc.  Started Chantix 01/23/2021, stopped smoking.  02/20/2021 Discontinued Chantix, still no smoking.  01/31/2021 occasional (5-10 times daily) dyspnea, frequent need to clear throat, constant sinus congestion with clear thin mucus.
100.5 F fever, feverish feeling, fatigued; very sore right shoulder; took 1 Tylenol, fever reduced to 99.3. Really wanted to lie down but had to work (sitting). Took 2 Ibuprophen ~ 8 PM same day. Tender shoulder well into Saturday evening.
Death diagnosed with covid pneumonia, hypoxia, acute respiratory failure, intubation, Death increased sob reported on 10/8/2021, recommended to go to ER. Patient admitted to Hospital. Death on 10/10/2021
3 days after the vaccine a sore throat developed; Inner ear problem; 6 hours after the injection arm became very sore.; This is a spontaneous report from a contactable pharmacist, the patient. A 61-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 21Apr2021 at 10:15 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included polycythemia vera and known allergies to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included duloxetine hydrochloride (CYMBALTA) and omeprazole (PRILOSEC), both for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 21Apr2021 at 16:15, 6 hours after, the patient experienced the injection arm became very sore. Pain persisted for 24 hours. On 24Apr2021 at 11:00, 3 days after the vaccine, the patient experienced a sore throat developed and inner ear problem manifested. Attempted to drain ear with a q-tip but made problem worse and had to see physician. The event inner ear problem resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had been tested for COVID-19. On 27Apr2021, the patient underwent PCR amplification test (nasal swab) and the result was negative. Therapeutic measures were taken as a result of inner ear problem which included treatment with ear lavage, antibiotics, hydrocortisone acetate/neomycin sulfate/polymyxin b sulfate (CORTISPORIN), otic solution. The clinical outcome of the event injection arm became very sore was recovered on 22Apr2021 at 16:15, after a duration of 24 hours. The clinical outcome of the event sore throat and inner ear problem was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
pt recvd vax; pt was given pcn as prophylactic therapy; after discontinuation of pcn, pt devel fever including musculoskeletal pain, headache, diarrhea, respiratory symptoms & lethargy; staining of CSF showed gram-pos diploccoci; pt died;
Approximately 1.5hrs after receiving the vaccination my vision began blurring. It's as if my eyes do not focus. I'm submitting this about 4 hours after receiving the vaccine and my vision is still blurred. I am not experiencing any other side-effects at this time except for a sore arm at the injection site.
Minor soreness in left shoulder (where vaccine was delivered); Very minor headache; This is a spontaneous report from a non-contactable consumer, the patient. A 45-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247) via an unspecified route of administration in the left arm on 23Mar2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have a history of allergies. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration as a single dose for COVID-19 immunisation on an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 23Mar2021 at 17:00, the patient experienced minor soreness in the left shoulder where vaccine was administered and a very minor headache. The patient did not receive any treatment for the reported events. Adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events shoulder soreness and the headache was resolving at the time of this report.  No follow-up attempts are possible. No further information expected.
Pt received IPV, DTAP on left deltoid. Mom noted small swelling before bedtime. The next morning had redness, swelling that progressed from shoulder down to elbow. Had decreased use of arm. Was given Tylenol and Keflex for possible cellulitis.
Rash w/localized inflammation in area of injection site from the DTaP and VARIVAX.
Left arm was hurting at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Left arm was hurting at injection site) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, the patient experienced VACCINATION SITE PAIN (Left arm was hurting at injection site). The patient was treated with PARACETAMOL (TYLENOL) for Vaccination site pain, at a dose of UNK dosage form. At the time of the report, VACCINATION SITE PAIN (Left arm was hurting at injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 13-May-2021: Additional information received included no new information.
Headache, Myalgia, NauseaVomiting, sore throat, fatigue Narrative:
i feel sick; my arm hurts; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (i feel sick) and PAIN IN EXTREMITY (my arm hurts) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MALAISE (i feel sick) and PAIN IN EXTREMITY (my arm hurts). At the time of the report, MALAISE (i feel sick) and PAIN IN EXTREMITY (my arm hurts) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported.                   No treatment medication was reported.
Mom reported baby had been sleepy since getting vaccines on 4/1/2019. Mom called on 4/2/2019 @ 8:45 pm to report the sleepiness and that baby had hives on left forearm and elbow. Blotchy area on right arm back and chest. Follow-up by phone 4/3/2019. Baby is eating well. Is alert and more wakeful. Marked decrease in all areas of redness.
Swelling of his right, upper eyelid; Low grade fever; Fatigue; Right eye swelled up; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received BNT162b2 (Pfizer BioNTech Covid-19 mRNA Vaccine, Solution for injection, Batch/Lot number and Expiration date was not reported), via an unspecified route of administration on 14Mar2021 as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On 15Mar2021, at 09:00 hours, patient had all the common symptoms included swelling of his right, upper eyelid, right eye swelled up, low grade fever and fatigue. Patient reported that it was because he did not see it in any of the material he had, or online. The outcome of all the events was unknown.   No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
Some pts had pain @ inject site p/1st dose, some p/2nd & some p/the third dose; No tx was given.
itching of her scalp; The patient did have a sore injection site arm after her Spikevax vaccine; developed a rash on her torso.; The rash itches a lot; This spontaneous case was reported by a patient and describes the occurrence of PRURITUS (itching of her scalp), RASH PRURITIC (The rash itches a lot), VACCINATION SITE PAIN (The patient did have a sore injection site arm after her Spikevax vaccine) and RASH (developed a rash on her torso.) in a 71-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. ASKU) for COVID-19 prophylaxis.     Concurrent medical conditions included Migraine. Concomitant products included RIMEGEPANT SULFATE (NURTEC ODT) for Migraine, BUDESONIDE and PANTOPRAZOLE for an unknown indication.    On 18-Oct-2023, the patient received sixth dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In October 2023, the patient experienced RASH PRURITIC (The rash itches a lot) and RASH (developed a rash on her torso.). On 18-Oct-2023,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024), the patient experienced VACCINATION SITE PAIN (The patient did have a sore injection site arm after her Spikevax vaccine). On 19-Oct-2023, the patient experienced PRURITUS (itching of her scalp). At the time of the report, PRURITUS (itching of her scalp), RASH PRURITIC (The rash itches a lot), VACCINATION SITE PAIN (The patient did have a sore injection site arm after her Spikevax vaccine) and RASH (developed a rash on her torso.) had not resolved.        For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not reported.  The patient received Moderna vaccines in the past on 25-Jan-2021 (Dose:1, lot number 028L20A, location: unknown), 22-Feb-2021 (Dose:2, lot number 015M20A, location: unknown), 26-Aug-2021 (Dose:3, lot number 088D21A, location: unknown), 05-Apr-2022 (Dose:4, lot number 048L21A, location: unknown) and experienced same reactions fever, chills, and aching all over every time. The patient received fifth Moderna bivalelnt vaccine on 11-Oct-2022, (lot number 050022A) and had a sore arm.  Treatment medication was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-747030, US-MODERNATX, INC.-MOD-2023-747032 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-747030:Same patient (different vaccine) US-MODERNATX, INC.-MOD-2023-747032:Master case
Pt recvd vax on 14SEP92 & on 16SEP92 devel soreness @ the inject site as well as 3 inch rash which was sl pruritic & painful; No further details were provided;
2 days, post vax, pt had seizure-like symptoms with rolling back of eyes and shaking of upper and lower extremities.
Began with head and neck tics on 3/6; progressed rapidly from 3/6 through 3/10 to include facial tics (blinking, head movement), oral tics (grimacing, clenching teeth, gulping air), uncontrolled verbal tics (yelping, loud humming); uncontrolled gross motor tics (foot stomping, arm and leg straightening, kicking, raising arms above head) These symptoms have never been experienced/witnessed prior to 3/6/2021
2-3 day after flu like symptoms, lethargy, fever to 100, initial insomnia for 4 days, tired, arthralgias, and headache.  Week 2 had had swollen node in bilat neck and axilla painful nodes.  All these resolved, however, continuous joint pain in the knees, ankles and hips have continued.  Worse in the AM.  This patient meets the criteria for Refractory Persistent Myalgia/ Arthralgia Syndrome (RPMAS) and will be added to the other 224 cases in our database, and will receive a permanent exemption to the anthrax vaccine.
Started gettting right frontal headaches the afternoon on the date I receiveed my Flu shot. I never get headaches.
Shoulder pain, mild back pain, mild numbness to arm, mild erythema and small bump at injection site.
Patient developed hives all over body. Patient came to clinic and patient's PCP, prescribed the patient BENADRYL.
patient got two primary series of pfizer after already having gotten one Janssen dose (this was prior to when boosters and third doses were allowed)